MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$1,398K
EPS
-$0.07
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Revenues
-0 --
Research and development
608 496 493 14
General and administrative
827 960 773 369
Total operating expenses
1,435 1,456 1,266 383
Loss from operations
-1,435 -1,456 -1,266 -383
Other nonoperating expense
---537
Interest income
37 34 4 -
Interest expense
-0 -12
Debt discount amortization
-0 -115
Total other income (expenses)
37 34 4 -664
Net loss
-1,398 -1,422 -1,262 -1,047
Basic
20,206,033 17,213,017 15,875,485 10,910,227
Basic loss per common share
-0.07 -0.08 -0.08 -0.1
Diluted
20,206,033 17,213,017 15,875,485 10,910,227
Diluted loss per common share
-0.07 -0.08 -0.08 -0.1
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$37K Net loss-$1,398K Total other income(expenses)$37K Loss from operations-$1,435K Total operatingexpenses$1,435K General andadministrative$827K Research and development$608K

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)